The stock of Grifols SA, Barcelona (NASDAQ:GRFS) is a huge mover today! About 718,549 shares traded hands or 2.08% up from the average. Grifols SA, Barcelona (NASDAQ:GRFS) has risen 2.04% since March 9, 2016 and is uptrending. It has underperformed by 5.38% the S&P500.
The move comes after 6 months negative chart setup for the $4.06B company. It was reported on Oct, 12 by Barchart.com. We have $14.35 PT which if reached, will make NASDAQ:GRFS worth $203.00 million less.
Analysts await Grifols SA, Barcelona (NASDAQ:GRFS) to report earnings on November, 2.
Grifols SA, Barcelona (NASDAQ:GRFS) Ratings Coverage
Out of 5 analysts covering Grifols SA (NASDAQ:GRFS), 2 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 40% are positive. Grifols SA has been the topic of 6 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Berenberg on Tuesday, February 9. Nomura initiated Grifols SA, Barcelona (NASDAQ:GRFS) on Thursday, March 17 with “Buy” rating. The firm has “Underweight” rating given on Monday, January 4 by Morgan Stanley. The rating was downgraded by Berenberg on Friday, November 20 to “Hold”. The stock has “Hold” rating given by HSBC on Wednesday, December 2.
According to Zacks Investment Research, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.”
Another recent and important Grifols SA, Barcelona (NASDAQ:GRFS) news was published by Forbes.com which published an article titled: “Grifols Barcelona Enters Oversold Territory (GRFS)” on August 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.